High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases-One with a remarkable thoracic response as well

Lung Cancer

Volumn 80, Issue 1, 2013, Pages 102-105

  Kuiper, J L ^a   Smit, E F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

EGFR; Erlotinib; Leptomeningeal metastases; Lung cancer; Pulsatile dosing; TKI

Indexed keywords

AFATINIB; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PEMETREXED; SORAFENIB;

ADULT; ARTICLE; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FEMALE; HEADACHE; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; MALAISE; MENINGEAL METASTASIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PULSATILE DRUG RELEASE; SKIN TOXICITY; TREATMENT RESPONSE; VOMITING;

CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; THORACIC DISEASES; TREATMENT OUTCOME;

EID: 84875250073     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.12.024     Document Type: Article

References (19)

1. Clarke J.L., Pao W., Wu N., Miller V.A., Lassman A.B. High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer. J Neurooncol 2010, 99(2):283-286.
2. Dhruva N., Socinski M.A. Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. J Clin Oncol 2009, 27(22):e31-e32.
3. Grommes C., Oxnard G.R., Kris M.G., Miller V.A., Pao W., Holodny A.I., et al. " Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro-Oncol 2011, 13(12):1364-1369.
4. Hata A., Kaji R., Fujita S., Katakami N. High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer. J Thorac Oncol 2011, 6(3):653-654.
5. Jackman D.M., Holmes A.J., Lindeman N., Wen P.Y., Kesari S., Borras A.M., et al. Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib. J Clin Oncol 2006, 24(27):4517-4520.
6. Togashi Y., Masago K., Fukudo M., Tsuchido Y., Okuda C., Kim Y.H., et al. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol 2011, 68(4):1089-1092.
7. Omuro A.M., Kris M.G., Miller V.A., Franceschi E., Shah N., Milton D.T., et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer 2005, 103(11):2344-2348.
8. Morris P.G., Reiner A.S., Szenberg O.R., Clarke J.L., Panageas K.S., Perez H.R., et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy. J Thorac Oncol 2012, 7(2):382-385.
9. Umemura S., Tsubouchi K., Yoshioka H., Hotta K., Takigawa N., Fujiwara K., et al. Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group. Lung Cancer 2012, 77(1):134-139.
10. Balak M.N., Gong Y., Riely G.J., Somwar R., Li A.R., Zakowski M.F., et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006, 12(21):6494-6501.
11. Hata A., Katakami N., Yoshioka H., Takeshita J., Tanaka K., Nanjo S., et al. Rebiopsy of non-small cell lung cancer patients with acquired resistance to EGFR-TKI: Comparison between T790M mutation-positive and -negative populations. J Clin Oncol 2012, 30(Suppl.). [abstr 7528, 1-6-2012].
12. Ruppert A.M., Beau-Faller M., Neuville A., Guerin E., Voegeli A.C., Mennecier B., et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. Eur Respir J 2009, 33(2):436-440.
13. Togashi Y., Masago K., Fukudo M., Terada T., Fujita S., Irisa K., et al. Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol 2010, 5(7):950-955.
14. Milton D.T., Azzoli C.G., Heelan R.T., Venkatraman E., Gomez J.E., Kris M.G., et al. A phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer. Cancer 2006, 107(5):1034-1041.
15. Herbst R.S., Giaccone G., Schiller J.H., Natale R.B., Miller V., Manegold C., et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004, 22(5):785-794.
16. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
17. Aerts J.G., Codrington H., Burgers S., Biesma B., Dalesio O., Dingemans A.-M.C., et al. A randomized phase II study comparing erlotinib versus erlotinib alternating with chemotherapy in relapsed non-small cell lung cancer (NSCLC) patients. ESMO (European Society of Medical Oncology) Congress 2012.
18. Mok T.S.K., Lee J.S., Zhang L., Yu C.-J., Thongprasert S., Ladrera G.E.I., et al. Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced non-small-cell lung cancer (NSCLC). ESMO (European Society of Medical Oncology) Congress 2012.
19. Sequist L.V., Waltman B.A., Dias-Santagata D., Digumarthy S., Turke A.B., Fidias P., et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011, 3(75):75ra26.